1. Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002;62:107-133.
[CROSSREF] [PUBMED]
2. Goya K, Otsuki M, Xu X, Kasayama S. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism 2003;52:192-198.
[CROSSREF] [PUBMED]
3. Shin S, Kim KJ, Chang HJ, Lee BW, Yang WI, Cha BS, et al. The effect of oral prostaglandin analogue on painful diabetic neuropathy: a double-blind, randomized, controlled trial. Diabetes Obes Metab 2013;15:185-188.
[CROSSREF]
4. Guan J, Long L, Chen YQ, Yin Y, Li L, Zhang CX, et al. Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy. Genet Mol Res 2014;13:4154-4158.
[CROSSREF] [PUBMED] [PDF]
5. Watanabe M, Nakashima H, Mochizuki S, Abe Y, Ishimura A, Ito K, et al. Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I(2) analog, beraprost sodium. Am J Nephrol 2009;30:1-11.
[CROSSREF] [PUBMED]
6. Yamashita T, Shikata K, Matsuda M, Okada S, Ogawa D, Sugimoto H, et al. Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats. Diabetes Res Clin Pract 2002;57:149-161.
[CROSSREF] [PUBMED]
7. Arima S, Ren Y, Juncos LA, Carretero OA, Ito S. Glomerular prostaglandins modulate vascular reactivity of the downstream efferent arterioles. Kidney Int 1994;45:650-658.
[CROSSREF] [PUBMED]
8. Owada A, Suda S, Hata T. Effect of long-term administration of prostaglandin I(2) in incipient diabetic nephropathy. Nephron 2002;92:788-796.
[CROSSREF] [PUBMED]
9. Lehmann ED, Riley WA, Clarkson P, Gosling RG. Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lancet 1997;350 Suppl 1:SI14-SI19.
[CROSSREF] [PUBMED]
10. Amar J, Ruidavets JB, Chamontin B, Drouet L, Ferrieres J. Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens 2001;19:381-387.
[CROSSREF] [PUBMED]
11. Shima A, Miyamoto M, Kubota Y, Takagi G, Shimizu W. Beraprost sodium protects against diabetic nephropathy in patients with arteriosclerosis obliterans: a prospective, randomized, open-label study. J Nippon Med Sch 2015;82:84-91.
[CROSSREF] [PUBMED]
12. Nakayama T, Hironaga T, Ishima H, Maruyama T, Masubuchi Y, Kokubun S. The prostacyclin analogue beraprost sodium prevents development of arterial stiffness in elderly patients with cerebral infarction. Prostaglandins Leukot Essent Fatty Acids 2004;70:491-494.
[CROSSREF] [PUBMED]
13. Nakayama T, Masubuchi Y, Kawauchi K, Masaki R, Hironaga T, Ishima H, et al. Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction. Prostaglandins Leukot Essent Fatty Acids 2007;76:309-314.
[CROSSREF] [PUBMED]
14. Chapleau CE, White RP. Effects of prostacyclin on the canine isolated basilar artery. Prostaglandins 1979;17:573-580.
[CROSSREF] [PUBMED]
15. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension 2009;54:1328-1336.
[CROSSREF] [PUBMED]
16. Kim HK, Kim CH, Kim EH, Bae SJ, Choe J, Park JY, et al. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: the Korean Heart Study. Diabetes Care 2013;36:328-335.
[CROSSREF] [PUBMED] [PMC]
17. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function. Circulation 2002;106:2085-2090.
[CROSSREF] [PUBMED]
18. Grassi G, Giannattasio C. Obesity and vascular stiffness: when body fat has an adverse impact on arterial dynamics. J Hypertens 2005;23:1789-1791.
[CROSSREF] [PUBMED]
19. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74:1143-1155.
[CROSSREF] [PUBMED] [PMC]
20. Makino H, Yamasaki Y, Haramoto T, Shikata K, Hironaka K, Ota Z, et al. Ultrastructural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy. Lab Invest 1993;68:45-55.
[PUBMED]
21. Koh E, Morimoto S, Jiang B, Inoue T, Nabata T, Kitano S, et al. Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells. Artery 1993;20:242-252.
[PUBMED]
22. Villa E, Rabano A, Ruilope LM, Garcia-Robles R. Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy. Am J Hypertens 1997;10:202-208.
[CROSSREF] [PUBMED] [PDF]
23. Wang LN, Tang Z, Shou I, Fukui M, Tomino Y. Effects of the PGI2 analog beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes. Nephron 1996;73:637-643.
[CROSSREF] [PUBMED]
24. Fujita T, Fuke Y, Satomura A, Hidaka M, Ohsawa I, Endo M, et al. PGl2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. Prostaglandins Leukot Essent Fatty Acids 2001;65:223-227.
[CROSSREF] [PUBMED]